1992
The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection
Graham N, Zeger S, Park L, Vermund S, Detels R, Rinaldo C, Phair J. The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1992, 326: 1037-1042. PMID: 1347907, DOI: 10.1056/nejm199204163261601.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionDevelopment of AIDSPneumocystis carinii pneumoniaPCP prophylaxisProlong survivalEarly treatmentRelative riskVirus infectionCell countUse of zidovudineUse of prophylaxisDiagnosis of AIDSHIV Type 1HIV-1 infectionBasis of CD4High-risk menInitial disease stateProbability of deathZidovudine usersZidovudine therapyImmunodeficiency syndromeCarinii pneumoniaClinical symptomsProphylaxis
1991
Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS
STUDY T, Graham N, Zeger S, Park L, Saah A, Phair J, Detels R, Vermund S, Ho M. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Lancet 1991, 338: 265-269. PMID: 1677108, DOI: 10.1016/0140-6736(91)90414-k.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAerosolsCD4-Positive T-LymphocytesEvaluation Studies as TopicFollow-Up StudiesHIV SeropositivityHIV-1HumansLeukocyte CountMalePentamidinePneumonia, PneumocystisProspective StudiesRegression AnalysisRisk FactorsTime FactorsTrimethoprim, Sulfamethoxazole Drug CombinationZidovudineConceptsPneumocystis carinii pneumoniaEffect of zidovudineHIV-1 infectionPCP prophylaxisProbability of progressionLymphocytes/First episodePneumocystis carinii pneumonia prophylaxisHIV-1-infected individualsHIV-1-seropositive menMonth intervalsPrimary PCP prophylaxisEfficacy of zidovudinePresence of HIVRate of progressionMultivariate log-linear modelPneumonia prophylaxisMore CD4Primary prophylaxisZidovudine therapyLymphocyte countCarinii pneumoniaClinical trialsObservational studyProphylaxisNational AIDS incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups.
Rosenberg PS, Gail MH, Schrager LK, Vermund SH, Creagh-Kirk T, Andrews EB, Winkelstein W, Marmor M, Des Jarlais DC, Biggar RJ. National AIDS incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1991, 4: 392-401. PMID: 2007974.Peer-Reviewed Original ResearchConceptsIntravenous drug usersAIDS incidence trendsIncidence trendsDrug usersHeterosexual contactSevere immunodeficiencyHeterosexual intravenous drug usersHuman immunodeficiency virus (HIV) infectionFavorable trendTransmission groupImmunodeficiency virus infectionIncidence of AIDSCases of AIDSZidovudine therapyTransfusion recipientsVirus infectionNumber of casesZidovudineNew York CityEarly cessationTherapyAIDSMenGay menSan FranciscoZidovudine use in AIDS-free HIV-1-seropositive homosexual men in the Multicenter AIDS Cohort Study (MACS), 1987-1989.
Graham NM, Zeger SL, Kuo V, Jacobson LP, Vermund SH, Phair JP, Detels R, Rinaldo CR, Saah AJ. Zidovudine use in AIDS-free HIV-1-seropositive homosexual men in the Multicenter AIDS Cohort Study (MACS), 1987-1989. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1991, 4: 267-76. PMID: 1671411.Peer-Reviewed Original ResearchConceptsHIV-1 seropositive homosexual menZidovudine useVisit 11Clinical variablesClinical trialsHomosexual menVisit 7Multicenter AIDS Cohort StudyLymphocytes/mm3Major clinical variablesClinical trial participationAIDS Cohort StudyClinical trial participantsSeropositive participantsZidovudine therapyCohort studyHigher treatment ratesLymphocyte levelsLymphocyte numbersNonclinical factorsAIDS patientsTrial participationSymptom statusOverall prevalenceOdds ratio